1.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

2.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

3.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

4.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

5.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

6.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

7.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

8.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

9.

Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases.

1.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

2.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

3.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

4.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

5.

SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.

1.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

2.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

3.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

4.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

5.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

6.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

7.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

8.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

9.

The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium.

1.

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

2.

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

3.

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

4.

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

5.

Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol

1.

Test selection for antibody detection according to the seroprevalence level of Schmallenberg virus in sheep

2.

Test selection for antibody detection according to the seroprevalence level of Schmallenberg virus in sheep

3.

Test selection for antibody detection according to the seroprevalence level of Schmallenberg virus in sheep

4.

Test selection for antibody detection according to the seroprevalence level of Schmallenberg virus in sheep

1.

Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up

2.

Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up

3.

Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up

4.

Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up

5.

Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up

1.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

2.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

3.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

4.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

5.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

6.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

7.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

8.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

9.

SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis.

1.

Q Fever Serological Survey and Associated Risk Factors in Veterinarians, Southern Belgium, 2013

2.

Q Fever Serological Survey and Associated Risk Factors in Veterinarians, Southern Belgium, 2013

3.

Q Fever Serological Survey and Associated Risk Factors in Veterinarians, Southern Belgium, 2013

4.

Q Fever Serological Survey and Associated Risk Factors in Veterinarians, Southern Belgium, 2013

5.

Q Fever Serological Survey and Associated Risk Factors in Veterinarians, Southern Belgium, 2013

1.

Laboratory Findings Suggesting an Association Between BoHV-4 and Bovine Abortions in Southern Belgium

2.

Laboratory Findings Suggesting an Association Between BoHV-4 and Bovine Abortions in Southern Belgium

3.

Laboratory Findings Suggesting an Association Between BoHV-4 and Bovine Abortions in Southern Belgium

4.

Laboratory Findings Suggesting an Association Between BoHV-4 and Bovine Abortions in Southern Belgium

5.

Laboratory Findings Suggesting an Association Between BoHV-4 and Bovine Abortions in Southern Belgium

1.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

2.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

3.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

4.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...

5.

Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective...